BOLALARDA GEMOFILIYA A INGIBITOR SHAKLINING RETROSPEKTIV TAHLILI
##article.subject##:
gemofiliya A, ingibitor shakli, VIII omil, Bethesda, ingibitor antitanalar titri##article.abstract##
VIII omil faolligining boshlang‘ich darajasi ingibitorlar rivojlanishining ishonchli klinik prediktori bo‘lib xizmat qila olmaydi. Ushbu asoratning yuqori chastotasini hisobga olgan holda, kasallik fenotipining og‘irligidan qat’i nazar, o‘rinbosar terapiya olayotgan barcha bemorlar uchun antitanalarni muntazam ravishda laboratoriya tekshiruvidan o‘tkazish maqsadga muvofiqdir.
Библиографические ссылки
Rumyantsev AG. Hemophilia A: challenges of real clinical practice. Russian Journal of Pediatric Hematology and Oncology. 2020;7(4S):3–6. (in Russ).
National Clinical Protocol for the Diagnosis and Treatment of Hemophilia A and B. Clinical Protocols 2024. Uzbekistan; 2024. (in Russ).
Rumyantsev AG, Zozulya NI, Zorenko AYu, et al. Diagnosis and treatment of hemophilia: national clinical guidelines. Moscow: National Medical Research Center for Hematology of the Ministry of Health of Russia; 2024. (in Russ).
Pshenichnikova OS, Surin VL. Genetic risk factors for the development of inhibitor hemophilia A. Genetics. 2021;57(8):859–870. (in Russ).
Zozulya NI, Chernov VM, Tarasova IS, Rumyantsev AG. Unresolved issues in medical care for patients with inhibitor hemophilia in Russia. Russian Journal of Pediatric Hematology and Oncology. 2019;6(2):48–53. (in Russ).
Barlamov PN, Vasilyeva ER, Golubeva ME, Zhelobov VG, Starikova OS, Shutylev AA. Acquired inhibitor hemophilia. Clinical Medicine. 2018;96(4):361–364. (in Russ).
Dmitriev EV, Lyubushkin AV. Medical prevention of inhibitor hemophilia A in high-risk patients. Hematology Transfusiology Eastern Europe. 2024;10(3):296–305. (in Russ).
